Full-Time

Associate Director

Marketing/Media Data Strategy

Posted on 9/16/2025

Deadline 10/3/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$137k - $235.8k/yr

+ Long-term Incentive Program

New Hope, PA, USA

In Person

The job is available in Titusville, New Jersey or Horsham, PA.

Category
Data & Analytics (1)
Required Skills
Word/Pages/Docs
Marketing
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • BA/BS undergraduate degree, preferably in Business, Technology, Analytics or Health Sciences is required.
  • Validated experience of 7+ years in roles related to data management, analytics, insights or other commercial analytics areas within the pharmaceutical or life sciences industry.
  • Validated expertise in data sourcing and acquisition to support HCP and DTC marketing use cases, applying various data sources such as 1st party marketing platforms, social media, third-party media agencies and publishers, display advertising, websites, paid search, and other digital channels.
  • Proven experience in leading marketing/media data.
  • Experience with customer engagement and content data and analytics within a pharmaceutical or healthcare environment.
  • Strong understanding of data governance, quality, and compliance standards.
  • Proficiency in cloud technologies, data pipelines, and real-time analytics platforms.
  • Strong collaboration, communication, and stakeholder engagement skills.
  • Ability to translate business needs into scalable data solutions and innovations.
  • Strong analytical tool kit is required, including modern business intelligence tools and infrastructure that allow for effective management of large data, as is proficiency with PowerPoint, Excel and Word.
  • Proven results as a project manager in cross-functional technology projects required.
  • Strong analytical and problem-solving ability, and business and data analysis with focus on cross multiple therapeutic areas.
  • Strong written and verbal communication skills are required, including ability to simplify complex technical issues.
  • Customer focus with building relationships, issue identification and resolution, problem-solving and project management skills.
  • Diligent and results-driven.
  • Ability to apply policies and standards consistently.
  • Vendor management (outsourced program management team)
Responsibilities
  • Own and drive the acquisition of marketing data sources across all brands, ensuring data quality and facilitating use cases that maximize value for J&J.
  • Lead and enhance various marketing data products related to HCP and consumers, such as 'Customer Engagements,' 'Content,' and other related assets. Drive product improvements, adoption strategy, and integration within the organization.
  • Collaborate with internal StAT teams and brand marketers to understand their needs, roadmaps, and business priorities. Define the data strategy, align priorities, and execute initiatives that deliver clear value by measuring data impact and return on investment.
  • Partner with the Media Excellence team to ensure timely, high-quality third-party marketing and campaign data acquisition, management, and deployment to meet business needs.
  • Support core business processes such as omni-channel reporting, marketing mix modeling, and campaign analytics to ensure data-driven decision-making.
  • Explore emerging data sources, including website data, publisher data, and AI-driven HCP and Consumer insights. Propose and assess the value of new or enhanced marketing data sets.
  • Accelerate speed to impact by connecting and automating data workflows across marketing platforms like C360, SFMC, Veeva, ODP(One Data Platform), and Adobe Workfront.
  • Develop and maintain a strategic roadmap to evolve the customer engagement and content data ecosystem, scaling capabilities to include new audiences and functionalities.
  • Promote and implement Data Governance policies and standards. Ensure ongoing data accuracy, consistency, and compliance. Serve as the primary point of contact within the business for data-related needs, queries, and issues.
  • Work with data stewards to validate and coordinate data activities for internal reports and field-based systems.
  • Lead initiatives in innovative data ingestion, processing, and cloud technology solutions to address sales and marketing use cases. Conduct research, experimentation, and collaborate with industry leaders to adopt protocols. Improve data processing efficiency and infrastructure reliability through testing and innovation.
Desired Qualifications
  • A master’s degree or equivalent experience is an asset.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Icotyde launches with 1,500 prescriptions, Guggenheim projects $14.9 billion peak sales.
  • Atraverse Medical acquisition bolsters HOTWIRE system for atrial fibrillation ablations.
  • ETHICON 4000 Stapler gains CE Mark, reducing surgical leaks costing €5,200 per case.

What critics are saying

  • Stelara sales plummet 60% to $656 million from Amgen and Samsung biosimilars.
  • Over 90,000 talc lawsuits trigger $966 million October 2025 verdict against J&J.
  • CARVYKTI manufacturing shortfalls cap multiple myeloma sales growth in 2026.

What makes Johnson & Johnson unique

  • Diversified revenue spans Innovative Medicine, MedTech, and consumer health segments.
  • DARZALEX sales hit $4 billion in Q1 2026, exceeding forecasts by $600 million.
  • CARTO System marks 30 years, powering AI-driven CARTOSOUND SONATA for electrophysiology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.

INACTIVE